When was Avanti Polar Lipids founded?

Avanti Polar Lipids was founded in 1969.

Where is Avanti Polar Lipids located?

Avanti Polar Lipids is headquartered in Alabaster, United States. It is registered at Alabaster, Alabama.

Who is the current CEO of Avanti Polar Lipids?

Walt Shaw of Avanti Polar Lipids.

How many employees does Avanti Polar Lipids have?

As of Apr 30, 2026, the latest employee count at Avanti Polar Lipids is 146.

Is Avanti Polar Lipids a funded company?

Avanti Polar Lipids is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does Avanti Polar Lipids rank among its competitors?

Avanti Polar Lipids ranks 5th amongst 35 active competitors, of which 6 are funded. It stands 6th in terms of total funding among its competitors. The most recent competitor to raise funding was Echelon Biosciences, which secured $399K in Sep, 2024.

Who are the top competitors of Avanti Polar Lipids?

Avanti Polar Lipids' top competitors include Iceni Glycoscience, Echelon Biosciences and GlyTech. Among them, Echelon Biosciences secured the most recent funding round in September, 2024.

Avanti Polar Lipids - 2026 Company Profile, Team & Competitors

Q: Is Avanti Polar Lipids an acquired company?

Avanti Polar Lipids got acquired by Croda on Jul 06, 2020.

Avanti Polar Lipids is an acquired company based in Alabaster (United States), founded in 1969 by Walt Shaw. It operates as a High-purity lipid tools and solutions for cutting-edge research and pharmaceutical applications. The company has 35 active competitors, including 6 funded and 3 that have exited. Its top competitors include companies like Iceni Glycoscience, Echelon Biosciences and GlyTech.

Company Details

High-purity lipid tools and solutions for cutting-edge research and pharmaceutical applications. They provide essential tools for researchers, offering a wide range of high-purity lipids, lipid mixtures, and custom synthesis services. They support fundamental research, diagnostics, lipidomics, and pharmaceutical development. Their offerings include formulations, adjuvant systems, and delivery solutions for nucleic acids, proteins, and small molecules. They provide analytical procedures, liposome preparation resources, and contract manufacturing services. They empower smart science to improve lives by delivering specialized research products needed to drive groundbreaking biochemistry research and advance the next-generation of pharmaceutical delivery systems. They offer products for research use only.

Website: avantilipids.com
Social
Email ID: *****@avantilipids.com
Phone Number: +1 **********
Registered Address: Alabaster, Alabama

Key Metrics

Founded Year

1969

Location

Alabaster, United States

Stage

Acquired

Ranked

5^th among 35 active competitors

Employee Count

146 as on Apr 30, 2026

Similar Companies

Iceni Glycoscience & 36 more

Exit Details

Acquired by Croda (Jul 06, 2020)

View Avanti Polar Lipids' full profile

Avanti Polar Lipids is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Avanti Polar Lipids Inc CIN: 630790131 , United States, Active	Dec 31, 1999	-	134 (As on Dec 31, 2020)	-

Avanti Polar Lipids got acquired by Croda on Jul 06, 2020 at an acquisition amount of $*****.

Click here to take a look at Avanti Polar Lipids's acquisition in detail

Avanti Polar Lipids has not raised any funding rounds yet.

The founders of Avanti Polar Lipids is Walt Shaw.

Here are the details of Avanti Polar Lipids' key team members:

Walt Shaw: Founder & CEO of Avanti Polar Lipids.

View details of Avanti Polar Lipids's Founder profiles and Board Members

Avanti Polar Lipids' employee count trend

Avanti Polar Lipids has 146 employees as of Apr 26. Here is Avanti Polar Lipids's employee count trend over the years:

Employee count trend for Avanti Polar Lipids

Uncover Avanti Polar Lipids' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Avanti Polar Lipids include Iceni Glycoscience, Echelon Biosciences and GlyTech. Here is the list of Top 10 competitors of Avanti Polar Lipids, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Iceni Glycoscience 2014, Norwich (United Kingdom), Seed	Provider of carbohydrate chemistry, glycobiology, and analytical services for diagnostics	$1.77M	New Anglia Local Enterprise Partnership, Europa	43/100
2nd	Echelon Biosciences 1997, Salt Lake City (United States), Acquired	Lipid and cell signaling solutions for diagnostics and drug treatments	-	NIH, National Science Foundation & 1 others	38/100
3rd	GlyTech 2012, Kyoto (Japan), Series B	Provider of human-type asparagine (Asp)-linked glycans for research applications	$9.13M	Yokogawa, Osaka University & 4 others	38/100
4th	GlycoSpot 2014, Frederiksberg (Denmark), Seed	Provider of solutions for high throughput enzyme screening	$3.58M	Capnova, Spring Nordic & 2 others	36/100
5th	Avanti Polar Lipids 1969, Alabaster (United States), Acquired	High-purity lipid tools and solutions for cutting-edge research and pharmaceutical applications	-	-	29/100
6th	ADDAX Biosciences 2017, Turin (Italy), Seed	Developer of a non-toxic formalin alternative tissue fixative. This fixative provides comparable or superior results to formalin in histological, immunohistochemical, and molecular analyses, while eliminating the carcinogenic and toxic risks associated with formalin use. The product is protected by an international patent and is designed for use in histology laboratories, improving both patient care and worker safety. The company collaborates with various research institutions to advance the application of this technology in different fields.	-	FT Partners, EIC Fund & 1 others	33/100
7th	GlycoScientific 2009, Athens (United States), Funding Raised	Glycobiology research reagents, antibodies, and standards for glycosylation characterization	-	Georgia Research Alliance, HHS	31/100
8th	TFChem 2007, Rouen (France), Funding Raised	Drug discovery platform exploiting fluoride chemistry to design glycomimetic compounds	-	Economy And Finance, Government of France ... & 4 others	30/100
9th	GlycoPath 2019, Charleston (United States), Seed	Developer of glycan assays for biomarker discovery	-	Bruker, HHS	30/100
10th	ProZyme 1990, Hayward (United States), Acquired	Life sciences, diagnostics, and applied markets solutions provider	$321K	-	28/100